IQVIA modeled the impact of expanding 340B patient eligibility under continuum-of-care rules. Results showed branded product sales could more than double, rising from $93B to $189B based on 2022 data, with variation across disease areas. The study raises concerns about disruption and lack of evidence that patients directly benefit from expansion. Conversion rates also suggest wide variability in adoption. Findings underscore the financial stakes and policy risks tied to potential program expansion, warranting further analysis.

Join for free to read